A Phase 1 interventional study of DS-8201a (DP1) and DS-8201a (DP2) in Advanced Solid Tumors, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.
Sponsored by Daiichi Sankyo Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of DS-8201a in participants with advanced solid malignant tumors.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 292 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1:
Part 2a:
Part 2b:
Part 2c:
Part 2d:
Satisfy at least one of the following criteria
Part 2e:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.
Drug: DS-8201a (DP1) · Drug: DS-8201a (DP)
Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), HER2 expressing other solid malignant tumor (Part 2d); HER2 expressing breast cancer (Japan only; Part 2e)
Drug: DS-8201a (DP1) · Drug: DS-8201a (DP2) · Drug: DS-8201a (DP)
DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.
DS-8201a (DP) is to be administered via intravenous (IV) dose.
Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)
Objective response rate (ORR) by independent central review was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
Time frame: From 6 months postdose of last participant up to 3 years 5 months
Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)
Disease control rate (DCR) by independent central review was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks (±1week) from the first dosing date. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.
Time frame: From 6 months postdose of last participant up to 3 years 5 months
Best Overall Response Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)
Best overall response by independent central review was defined as the proportion of participants who achieved either complete response \[CR\], partial response \[PR\], stable disease (SD), progressive disease (PD), or were non-evaluable (NE) as per RECIST v1.1. CR was defined as a disappearance of all target lesions, PR at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.
Time frame: From 6 months postdose of last participant up to 3 years 5 months
Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
Duration of response (DoR) by independent central review was defined as the time between the date of the first complete response (CR) or partial response (PR) until the date of the first documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and PD as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
Time frame: From 6 months postdose of last participant up to 3 years 5 months
Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
Time frame: From 6 months postdose of last participant up to 3 years 5 months
Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
Time frame: From 6 months postdose of last participant up to 3 years 5 months
Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
Time frame: From 6 months postdose of last participant up to 3 years 5 months
Pharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum DS-8201a Following First Dose
The serum PK parameters of DS-8201a and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.
Time frame: Post first dose up to Day 147
Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose
The serum PK parameters Maximum (peak) Observed serum concentration of DS-8201a and its analytes were estimated using standard non-compartmental method.
Time frame: Post first dose up to Day 147
Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose
The serum PK parameters of Time of maximum plasma concentration (Tmax) for DS-8201a and its analytes were estimated using standard non-compartmental methods.
Time frame: Post first dose up to Day 147
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose
The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.
Time frame: Post first dose up to Day 147
Overview of Treatment-emergent Adverse Events
Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Events, v4.03.
Time frame: Baseline up to 28 days after the last dose of study drug, up to 3 years 5 months
A total of 292 participants who met all inclusion and no exclusion criteria were enrolled at 8 centers in the US and 6 centers in Japan. A total of 27 participants started the Dose Escalation phase and a total of 265 participants in the Dose Expansion phase.
| Milestone | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 3 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease per recist | 2 | 3 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing | 1 | 0 | 0 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 49 | 62 | 20 | 33 | 17 | 24 | 18 | 20 | 22 |
| Enrolled, but not dosed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 49 | 62 | 20 | 33 | 17 | 24 | 18 | 20 | 22 |
| Withdrew: Progressive disease per recist | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 17 | 8 | 16 | 13 | 19 | 10 | 13 | 11 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 12 | 0 | 3 | 2 | 0 | 1 | 3 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 22 | 0 | 11 | 0 | 5 | 2 | 2 | 1 |
| Withdrew: Ongoing | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 10 | 11 | 3 | 0 | 0 | 4 | 0 | 6 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Did not receive treatment | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Objective response rate (ORR) by independent central review was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
| percentage of participants | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) | 0 (0 to 70.8) | 33.3 (0.8 to 90.6) | 0 (0 to 70.8) | 83.3 (35.9 to 99.6) | 33.3 (4.3 to 77.7) | 50.0 (11.8 to 88.2) | 51.0 (36.6 to 65.2) | 53.7 (41.1 to 66.0) | 33.3 (14.6 to 57.0) | 39.4 (22.9 to 57.9) | 26.3 (9.1 to 51.2) | 32.0 (14.9 to 53.5) | 55.6 (30.8 to 78.5) | 5.0 (0.1 to 24.9) | 30.4 (13.2 to 52.9) |
Disease control rate (DCR) by independent central review was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks (±1week) from the first dosing date. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.
| percentage of participants | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) | 100.0 (29.2 to 100.0) | 100.0 (29.2 to 100.0) | 66.7 (9.4 to 99.2) | 100.0 (54.1 to 100.0) | 100.0 (54.1 to 100.0) | 100.0 (54.1 to 100.0) | 88.2 (76.1 to 95.6) | 95.5 (87.5 to 99.1) | 85.7 (63.7 to 97.0) | 87.9 (71.8 to 96.6) | 78.9 (54.4 to 93.9) | 88.0 (68.8 to 97.5) | 83.3 (58.6 to 96.4) | 80.0 (56.3 to 94.3) | 82.6 (61.2 to 95.0) |
Best overall response by independent central review was defined as the proportion of participants who achieved either complete response \[CR\], partial response \[PR\], stable disease (SD), progressive disease (PD), or were non-evaluable (NE) as per RECIST v1.1. CR was defined as a disappearance of all target lesions, PR at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.
| Participants | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete response | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 8 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Partial response | 0 | 1 | 0 | 4 | 1 | 3 | 24 | 28 | 7 | 13 | 5 | 7 | 10 | 1 | 5 |
| Stable disease | 3 | 2 | 2 | 1 | 4 | 3 | 19 | 28 | 11 | 16 | 10 | 14 | 5 | 15 | 12 |
| Progressive disease | 0 | 0 | 1 | 0 | 0 | 0 | 4 | 1 | 3 | 3 | 4 | 3 | 2 | 2 | 3 |
| Non-evaluable | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 2 | 1 |
Duration of response (DoR) by independent central review was defined as the time between the date of the first complete response (CR) or partial response (PR) until the date of the first documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and PD as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
| months | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases) | 12.7 (6.7 to NA) | 13.6 (7.3 to NA) | NA (NA to NA) | 10.4 (3.4 to NA) | 5.6 (2.9 to NA) | 6.9 (3.5 to NA) | 10.7 (6.9 to 11.5) | 13.4 (NA to NA) | NA (3.0 to NA) |
Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
| months | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|
| Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases) | 2.7 (1.5 to 2.9) | 2.8 (1.4 to 2.9) | 2.6 (1.2 to 4.2) | 2.7 (1.2 to 3.1) | 1.6 (1.2 to 3.1) | 2.2 (1.4 to 2.9) | 1.4 (1.2 to 2.8) | 3.0 (NA to NA) | 1.6 (1.2 to 2.9) |
Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
| months | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|
| Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases) | 13.7 (8.5 to 19.6) | 14.1 (8.5 to NA) | NA (2.7 to NA) | 11.1 (5.0 to NA) | 4.3 (2.6 to 8.6) | 8.2 (4.2 to 11.0) | 11.3 (7.2 to 14.3) | 4.0 (2.7 to 5.6) | 11.0 (2.8 to NA) |
Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.
| months | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|
| Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases) | NA (NA to NA) | NA (26.4 to NA) | NA (NA to NA) | 19.7 (12.5 to 29.4) | 18.9 (5.7 to NA) | 26.2 (10.0 to NA) | NA (17.3 to NA) | 15.6 (4.8 to NA) | 23.4 (9.7 to NA) |
The serum PK parameters of DS-8201a and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.
| ug*d/mL | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing Other Solid Tumors | Dose Expansion: HER2-expressing Breast Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUClast | 51.7 ± 13.1 | 116 ± 58.7 | 325 ± 142 | 544 ± 165 | 901 ± 155 | 996 ± 229 | 559 ± 178 | 785 ± 228 | 581 ± 180 | 693 ± 178 | 542 ± 163 | 507 ± 126 | 631 ± 184 | 693 ± 102 |
| AUCinfinity | 55.0 ± 11.9 | 121 ± 58.9 | 340 ± 150 | 590 ± 186 | 1030 ± 209 | 1100 ± 259 | 602 ± 203 | 848 ± 243 | 589 ± 145 | 762 ± 205 | 596 ± 183 | 563 ± 151 | 683 ± 209 | 753 ± 118 |
The serum PK parameters Maximum (peak) Observed serum concentration of DS-8201a and its analytes were estimated using standard non-compartmental method.
| ug/mL | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing Other Solid Tumors | Dose Expansion: HER2-expressing Breast Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose | 22.9 ± 3.76 | 36.2 ± 4.98 | 78.2 ± 16.1 | 127 ± 17.2 | 181 ± 33.1 | 221 ± 41.0 | 126 ± 37.7 | 170 ± 53.6 | 133 ± 18.3 | 155 ± 33.2 | 113 ± 30.0 | 116 ± 21.1 | 150 ± 30.3 | 155 ± 21.4 |
The serum PK parameters of Time of maximum plasma concentration (Tmax) for DS-8201a and its analytes were estimated using standard non-compartmental methods.
| hours | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing Other Solid Tumors | Dose Expansion: HER2-expressing Breast Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose | 1.95 (1.62 to 1.98) | 4.03 (1.87 to 4.08) | 4.12 (1.95 to 6.88) | 2.02 (1.87 to 2.07) | 2.06 (1.50 to 3.97) | 1.97 (1.70 to 6.80) | 2.00 (1.50 to 6.85) | 2.08 (1.53 to 7.05) | 2.16 (1.50 to 7.07) | 2.00 (1.50 to 6.67) | 2.03 (1.58 to 4.08) | 1.95 (1.53 to 7.00) | 2.02 (1.50 to 7.20) | 2.05 (1.62 to 7.23) |
The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.
| days | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing Other Solid Tumors | Dose Expansion: HER2-expressing Breast Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose | 2.18 ± 0.671 | 3.07 ± 1.22 | 4.23 ± 1.24 | 6.03 ± 0.603 | 7.33 ± 1.64 | 6.44 ± 0.793 | 5.52 ± 1.23 | 6.00 ± 1.22 | 5.28 ± 1.49 | 5.79 ± 1.01 | 6.18 ± 1.18 | 5.90 ± 1.57 | 5.61 ± 1.29 | 5.46 ± 1.02 |
Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Events, v4.03.
| Participants | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent adverse events (TEAEs) | 3 | 3 | 3 | 6 | 6 | 6 | 50 | 66 | 20 | 33 | 19 | 25 | 59 |
| Drug-related TEAEs | 3 | 2 | 2 | 6 | 6 | 6 | 50 | 66 | 20 | 33 | 18 | 25 | 59 |
| TEAEs ≥Grade 3 | 0 | 0 | 0 | 5 | 2 | 2 | 23 | 42 | 11 | 23 | 10 | 20 | 37 |
| Drug-related TEAEs ≥Grade 3 | 0 | 0 | 0 | 3 | 2 | 2 | 18 | 37 | 8 | 20 | 8 | 16 | 30 |
| Serious TEAEs (including AEs ending in death) | 0 | 0 | 0 | 1 | 1 | 1 | 11 | 17 | 3 | 12 | 4 | 7 | 18 |
| Drug-related serious TEAEs | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 11 | 2 | 8 | 1 | 3 | 9 |
| TEAEs associated with death | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 2 | 0 | 1 | 5 |
| Drug-related TEAEs associated with death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 2 |
| TEAEs associated with discontinuation of drug | 0 | 0 | 0 | 0 | 1 | 3 | 7 | 22 | 0 | 11 | 0 | 4 | 5 |
| Related TEAEs associated with drug discontinuation | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 21 | 0 | 11 | 0 | 3 | 5 |
| TEAEs associated with dose reduction | 0 | 0 | 0 | 2 | 3 | 2 | 5 | 18 | 3 | 9 | 5 | 9 | 14 |
| Drug-related TEAEs associated with dose reduction | 0 | 0 | 0 | 2 | 3 | 2 | 4 | 18 | 2 | 9 | 4 | 9 | 13 |
| TEAEs associated with dose interruption | 1 | 1 | 0 | 6 | 4 | 3 | 21 | 36 | 8 | 13 | 9 | 13 | 22 |
| Related TEAEs associated with dose interruption | 1 | 0 | 0 | 3 | 3 | 2 | 15 | 28 | 7 | 11 | 5 | 11 | 17 |
Collected over Treatment-emergent adverse event (TEAE) data were collected from baseline up to 28 days after the last dose of study drug, up to 3 years 5 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: Cohort 1, 0.8 mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation: Cohort 2, 1.6 mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation: Cohort 3, 3.2 mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation: Cohort 4, 5.4 mg/kg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Dose Escalation: Cohort 5, 6.4 mg/kg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Dose Escalation: Cohort 6, 8.0 mg/kg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | 3/50 (6%) | 11/50 (22%) | 50/50 (100%) |
| Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | 1/66 (1.5%) | 17/66 (25.8%) | 66/66 (100%) |
| Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | 0/21 (0%) | 3/21 (14.3%) | 20/21 (95.2%) |
| Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | 0/33 (0%) | 12/33 (36.4%) | 33/33 (100%) |
| Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | 1/19 (5.3%) | 4/19 (21.1%) | 19/19 (100%) |
| Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | 1/25 (4%) | 7/25 (28%) | 25/25 (100%) |
| Dose Expansion: HER2-expressing Other Solid Tumors | 5/59 (8.5%) | 18/59 (30.5%) | 59/59 (100%) |
| Event | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soft tissue infectionInfections and infestations | 0/3 | 0/3 | 0/3 | 1/6 | 0/6 | 0/6 | 1/50 | 0/66 | 0/21 | 0/33 | 0/19 | 0/25 | 0/59 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 1/6 | 0/6 | 0/6 | 1/50 | 0/66 | 1/21 | 1/33 | 0/19 | 0/25 | 3/59 |
| Intestinal perforationGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 1/6 | 0/50 | 0/66 | 0/21 | 0/33 | 0/19 | 0/25 | 0/59 |
| CholangitisHepatobiliary disorders | 0/3 | 0/3 | 0/3 | 0/6 | 1/6 | 0/6 | 0/50 | 0/66 | 0/21 | 0/33 | 0/19 | 2/25 | 1/59 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/50 | 2/66 | 0/21 | 1/33 | 0/19 | 3/25 | 2/59 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 2/50 | 0/66 | 0/21 | 0/33 | 2/19 | 1/25 | 0/59 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 3/50 | 2/66 | 0/21 | 3/33 | 0/19 | 1/25 | 1/59 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 4/50 | 0/66 | 0/21 | 1/33 | 0/19 | 0/25 | 1/59 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/50 | 1/66 | 0/21 | 2/33 | 0/19 | 0/25 | 0/59 |
| Platelet count decreasedInvestigations | 0/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/50 | 4/66 | 0/21 | 2/33 | 0/19 | 1/25 | 2/59 |
| Event | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing Other Solid Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/3 | 1/3 | 2/3 | 6/6 | 4/6 | 4/6 | 43/50 | 52/66 | 15/21 | 26/33 | 12/19 | 19/25 | 44/59 |
| FatigueGeneral disorders | 3/3 | 0/3 | 0/3 | 0/6 | 3/6 | 4/6 | 24/50 | 32/66 | 11/21 | 9/33 | 4/19 | 3/25 | 21/59 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 1/3 | 1/3 | 4/6 | 4/6 | 2/6 | 23/50 | 47/66 | 7/21 | 20/33 | 8/19 | 22/25 | 35/59 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/3 | 0/3 | 1/3 | 2/6 | 3/6 | 3/6 | 19/50 | 45/66 | 6/21 | 18/33 | 4/19 | 4/25 | 20/59 |
| HeadacheNervous system disorders | 2/3 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 8/50 | 11/66 | 0/21 | 4/33 | 4/19 | 0/25 | 4/59 |
| VomitingGastrointestinal disorders | 1/3 | 1/3 | 2/3 | 1/6 | 4/6 | 0/6 | 28/50 | 35/66 | 10/21 | 14/33 | 3/19 | 8/25 | 31/59 |
| ConstipationGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 4/6 | 2/6 | 1/6 | 18/50 | 30/66 | 7/21 | 14/33 | 5/19 | 7/25 | 16/59 |
| Platelet count decreasedInvestigations | 0/3 | 0/3 | 1/3 | 4/6 | 3/6 | 3/6 | 15/50 | 24/66 | 3/21 | 14/33 | 5/19 | 12/25 | 22/59 |
| Neutrophil count decreasedInvestigations | 0/3 | 1/3 | 0/3 | 4/6 | 2/6 | 1/6 | 12/50 | 25/66 | 3/21 | 13/33 | 2/19 | 12/25 | 21/59 |
| Electrocardiogram QT prolongedInvestigations | 2/3 | 0/3 | 0/3 | 1/6 | 0/6 | 0/6 | 5/50 | 6/66 | 4/21 | 1/33 | 1/19 | 0/25 | 1/59 |
Demographic and baseline characteristics were assessed in the Enrolled Analysis Set (Dose Escalation, n=27; Dose Expansion, n=265).
| Age, Categorical(Participants) | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 2 | 2 | 4 | 2 | 33 | 48 | 14 | 25 | 6 | 8 | 12 | 16 | 16 | 191 |
| >=65 years | 1 | 2 | 1 | 4 | 2 | 4 | 16 | 14 | 6 | 8 | 11 | 16 | 6 | 4 | 6 | 101 |
| Age, Continuous(years) | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 59.3 ± 7.09 | 66.3 ± 4.73 | 48.3 ± 14.57 | 66.8 ± 14.82 | 58.2 ± 10.40 | 66.2 ± 10.67 | 56.2 ± 12.11 | 54.9 ± 10.28 | 57.8 ± 9.68 | 56.3 ± 10.97 | 64.2 ± 11.00 | 66.2 ± 8.55 | 57.4 ± 15.29 | 59.5 ± 9.90 | 58.5 ± 10.16 | 58.1 ± 11.39 |
| Sex: Female, Male(Participants) | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 3 | 6 | 6 | 5 | 48 | 62 | 20 | 33 | 5 | 4 | 13 | 9 | 9 | 229 |
| Male | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 12 | 20 | 5 | 11 | 13 | 63 |
| Race (NIH/OMB)(Participants) | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 3 | 3 | 3 | 6 | 6 | 3 | 25 | 40 | 6 | 23 | 11 | 24 | 9 | 17 | 14 | 193 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 8 |
| White | 0 | 0 | 0 | 0 | 0 | 3 | 19 | 19 | 12 | 7 | 5 | 0 | 8 | 3 | 7 | 83 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 4 |
| Region of Enrollment(participants) | Dose Escalation: Cohort 1, 0.8 mg/kg | Dose Escalation: Cohort 2, 1.6 mg/kg | Dose Escalation: Cohort 3, 3.2 mg/kg | Dose Escalation: Cohort 4, 5.4 mg/kg | Dose Escalation: Cohort 5, 6.4 mg/kg | Dose Escalation: Cohort 6, 8.0 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | Dose Expansion: HER2-expressing NSCLC Tumors | Dose Expansion: HER2-expressing Colorectal Tumors | Dose Expansion: HER2-expressing Other Solid Tumors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 0 | 0 | 0 | 0 | 0 | 3 | 30 | 25 | 16 | 11 | 5 | 0 | 10 | 3 | 9 | 112 |
| Japan | 3 | 3 | 3 | 6 | 6 | 3 | 19 | 37 | 4 | 22 | 12 | 24 | 8 | 17 | 13 | 180 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Sep 2015 to primary completion in Feb 2019, 41 months.
Results were first posted in Jun 2021, 2 years 4 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 41 months is close to that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan